-
公开(公告)号:US20090062528A1
公开(公告)日:2009-03-05
申请号:US12229277
申请日:2008-08-20
申请人: Brian C. Austad , Louis Grenier , Edward B. Holson , John J. Lee , Roger H. Pak , James R. Porter , James L. Wright
发明人: Brian C. Austad , Louis Grenier , Edward B. Holson , John J. Lee , Roger H. Pak , James R. Porter , James L. Wright
IPC分类号: C07D225/06
CPC分类号: A61K9/146 , A61K31/33 , C07D225/04
摘要: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
摘要翻译: 特别地,本文提供了固体形式的格尔德霉素类似物,包含格尔德霉素类似物和结晶抑制剂的药物组合物,制备和使用这些组合物的方法。 另外,提供了用于治疗癌症,肿瘤疾病状态和/或过度增殖性疾病的方法,以及抑制热休克蛋白90(“Hsp90”)的方法。
-
72.
公开(公告)号:US20110028482A1
公开(公告)日:2011-02-03
申请号:US12782655
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/498 , C07D413/04 , A61K31/42 , C07D417/14 , A61K31/4439 , C07D401/14 , A61K31/506 , A61K31/427 , C07D401/04 , A61K31/454 , C07D413/06 , A61K31/496 , C07D417/10 , A61K31/428 , C07D403/10 , C07D401/10 , A61K31/4709 , A61P1/00 , A61P3/00 , A61P9/00 , A61P17/00 , A61P25/00 , A61P27/06 , A61P29/00
CPC分类号: C07D413/04 , C07D261/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US20090069281A1
公开(公告)日:2009-03-12
申请号:US12229326
申请日:2008-08-20
申请人: Brian C. Austad , Louis Grenier , Edward B. Holson , John J. Lee , Roger H. Pak , James R. Porter , James L. Wright
发明人: Brian C. Austad , Louis Grenier , Edward B. Holson , John J. Lee , Roger H. Pak , James R. Porter , James L. Wright
IPC分类号: A61K31/395 , A61P35/00 , A61P35/02 , C07D225/06
CPC分类号: A61K9/146 , A61K31/33 , C07D225/04
摘要: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
-
公开(公告)号:USD282192S
公开(公告)日:1986-01-14
申请号:US513442
申请日:1983-07-13
申请人: Louis Grenier
设计人: Louis Grenier
-
公开(公告)号:US09149465B2
公开(公告)日:2015-10-06
申请号:US12782650
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: C07D261/04 , A61K31/5377 , A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
CPC分类号: A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US08765735B2
公开(公告)日:2014-07-01
申请号:US12782658
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A01N43/00 , A61K31/55 , A01N43/42 , A61K31/44 , A01N43/80 , A61K31/42 , C07D261/02 , C07D401/00
CPC分类号: C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US08283343B2
公开(公告)日:2012-10-09
申请号:US12229277
申请日:2008-08-20
申请人: Brian C. Austad , Louis Grenier , Edward B. Holson , John J. Lee , Roger H. Pak , James R. Porter , James L. Wright
发明人: Brian C. Austad , Louis Grenier , Edward B. Holson , John J. Lee , Roger H. Pak , James R. Porter , James L. Wright
CPC分类号: A61K9/146 , A61K31/33 , C07D225/04
摘要: Amorphous, polymorphic, and solvated forms of 17-amino geldanamycin are disclosed. These compounds are particularly useful for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and inhibiting Heat Shock Protein 90 (“Hsp90”).
摘要翻译: 公开了17-氨基格尔德霉素的无定形,多晶型和溶剂化形式。 这些化合物特别可用于治疗癌症,肿瘤疾病状态和/或过度增殖性疾病,并且抑制热休克蛋白90(Hsp90)。
-
公开(公告)号:US20110028478A1
公开(公告)日:2011-02-03
申请号:US12782650
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/5377 , C07D261/04 , A61K31/42 , A61P29/00 , A61P27/06 , A61P9/10 , A61P37/00 , A61P17/00 , A61P25/28 , A61P1/08 , A61P25/30 , A61P9/12 , A61P3/04 , C07D413/12 , A61K31/4439 , A61K31/506 , A61K31/501 , C07D413/10 , A61K31/4245 , A61K31/4709
CPC分类号: A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号:US20080221077A1
公开(公告)日:2008-09-11
申请号:US12001239
申请日:2007-12-11
申请人: Brian C. Austad , Louis Grenier , Edward B. Holson , John J. Lee , Roger H. Pak , James R. Porter , James L. Wright
发明人: Brian C. Austad , Louis Grenier , Edward B. Holson , John J. Lee , Roger H. Pak , James R. Porter , James L. Wright
IPC分类号: A61K31/397 , A61K31/395 , C07D225/06 , A61P35/00 , A61K31/40
CPC分类号: A61K9/146 , A61K31/33 , C07D225/04
摘要: Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”).
摘要翻译: 特别地,本文提供了固体形式的格尔德霉素类似物,包含格尔德霉素类似物和结晶抑制剂的药物组合物,制备和使用这些组合物的方法。 另外,提供了用于治疗癌症,肿瘤疾病状态和/或过度增殖性疾病的方法,以及抑制热休克蛋白90(“Hsp90”)的方法。
-
-
-
-
-
-
-
-